EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
|Videos|March 14, 2022
Dr. Maralani describes her experience with OAB treatment InterStim
Author(s)Urology Times staff
“I think this really gave us an advantage to offer better care,” says Shiva J. Maralani, MD.
Advertisement
In this video, Shiva J. Maralani, MD, discusses InterStim, a sacral nerve stimulation procedure used to treat patients with overactive bladder. Maralani and her team were recently awarded Medtronic’s Center of Excellence Designation for this treatment. Maralani is a urologist at the Michigan Institute of Urology in Saint Clair Shores and Utica, Michigan.
Advertisement
Related to this article
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
A recap of the FDA submissions and regulatory decisions in urology from August 2026.
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5